Cite

HARVARD Citation

    Mistry, P. et al. (2021). Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. American journal of hematology. 96 (9), pp. 1156-1165. [Online]. 
  
Back to record